| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 597.95M | 504.42M | 400.07M | 353.79M | 206.32M | 179.37M |
| Gross Profit | 170.50M | 146.69M | 112.22M | 90.26M | 51.11M | 44.68M |
| EBITDA | 112.05M | 95.80M | 68.95M | 67.37M | 29.65M | 24.63M |
| Net Income | 67.12M | 58.98M | 44.92M | 41.79M | 15.89M | 13.37M |
Balance Sheet | ||||||
| Total Assets | 652.82M | 629.00M | 404.14M | 378.19M | 334.13M | 203.20M |
| Cash, Cash Equivalents and Short-Term Investments | 18.23M | 13.45M | 5.26M | 4.45M | 11.12M | 24.23M |
| Total Debt | 165.51M | 206.03M | 46.04M | 68.37M | 84.36M | 2.21M |
| Total Liabilities | 248.91M | 286.24M | 118.05M | 140.65M | 139.69M | 26.31M |
| Stockholders Equity | 403.91M | 342.76M | 286.09M | 237.54M | 194.45M | 176.89M |
Cash Flow | ||||||
| Free Cash Flow | 54.88M | 56.94M | 30.84M | 3.96M | 8.90M | 20.67M |
| Operating Cash Flow | 63.56M | 66.59M | 41.33M | 17.74M | 14.29M | 25.04M |
| Investing Cash Flow | -12.35M | -210.16M | -10.49M | 1.29M | -101.46M | -4.26M |
| Financing Cash Flow | -52.50M | 152.39M | -30.02M | -25.89M | 74.05M | -285.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.73B | 26.06 | 18.31% | ― | 29.47% | 23.24% | |
74 Outperform | $1.42B | 18.77 | 4.77% | ― | -0.23% | ― | |
67 Neutral | $1.23B | 19.33 | 6.60% | 1.98% | 4.69% | -51.57% | |
58 Neutral | $2.24B | -194.83 | -2.45% | ― | 9.81% | -1067.00% | |
58 Neutral | $830.51M | -39.62 | -12.91% | ― | 23.27% | 43.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $1.02B | -2.02 | -38.71% | ― | 4.99% | -7151.40% |
UFP Technologies has released updated presentation materials for investor meetings, highlighting its strategic focus on high-margin, long-term manufacturing opportunities in the medical device market. The company emphasizes its expertise in design, materials, and global manufacturing, aiming to strengthen customer relationships and expand its presence in various markets, including medical, aerospace, and defense. The announcement underscores UFP Technologies’ commitment to innovation and growth, with potential implications for stakeholders in terms of increased production capacity and market expansion.
On December 1, 2025, UFP Technologies announced the retirement of its long-serving CEO, R. Jeffrey Bailly, effective June 4, 2026. Bailly, who has led the company for 31 years, will transition to the role of Executive Chairman of the Board. Mitchell Rock, currently the President of UFP Technologies, will succeed Bailly as CEO. Rock has been with the company since 1991 and has held various leadership roles, demonstrating a deep understanding of the markets UFP serves. This leadership transition is expected to continue the company’s strategic growth and maintain its strong market position.